Avid Technology: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Avid Technology ( AVID) fell in late trades on Wednesday after the digital audio and video equipment company gave a weak first-quarter outlook.

Citing weak demand from "creative enthusiast portion" of its business, the Burlington, Mass.-based company said it now sees a non-GAAP operating loss of $8 million in the March-ended period on revenue of $152 million. The average estimate of analysts polled by Thomson Reuters is for earnings of 3 cents a share on revenue of $161.1 million.

The stock was last quoted at $8.61, down 16.2%, on volume of nearly 15,000, according to Nasdaq.com. Based on Wednesday's regular-session close at $10.28, the shares were up 20% so far in 2012.

Wall Street was skeptical about Avid before this news with four of the five analysts covering the stock at hold. The median 12-month price target sits at $11.

Check out TheStreet's quote page for Avid Technology for year-to-date share performance, analyst ratings, earnings estimates and much more.

Pacira Pharmaceuticals

Shares of Pacira Pharmaceuticals ( PCRX) dipped nearly 2% in the extended session after the Parsippany, N.J.-based drug developer said it's launched a public offering of common stock.

The company didn't disclose details on the size or pricing of the stock sale. The stock was last quoted at $9.95, down 17 cents, on volume of 37,000, according to Nasdaq.com.

Pacira announced commercial availability of Exparel, a non-opioid pain relief product that's deployed as single-dose local administration at the surgical site, on Monday. The stock is up more than 20% in 2012, and more than 40% in the past year.

Check out TheStreet's quote page for Pacira for year-to-date share performance, analyst ratings, earnings estimates and much more.

-- Written by Michael Baron in New York.

>To contact the writer of this article, click here: Michael Baron.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Opinion

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Latest Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Elon Musk's Twitter Tirade Is the Dumbest Thing on Wall Street

Why Google's Search Momentum Won't Be Badly Hurt by New EU Rules

Why Google's Search Momentum Won't Be Badly Hurt by New EU Rules

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Time to Talk Tesla: What Happened This Week, Elon?

Time to Talk Tesla: What Happened This Week, Elon?